Multiple Myeloma Prognosis and Survival Rates by Age

Age at diagnosis is the single strongest demographic predictor of how long someone with multiple myeloma will survive, though the relationship is less straightforward than “older equals worse.” The median age at diagnosis sits around 69, and five-year relative survival for patients diagnosed before 70 has nearly doubled since the mid-1980s. Improvements for those diagnosed after 70 have been slower and more uneven, and a growing body of research suggests that physical fitness predicts outcomes more reliably than the number on a birth certificate.

How Survival Rates Have Shifted Over Time and by Age

A population-based study from New South Wales tracked myeloma survival across three treatment eras. For people diagnosed before age 70, the five-year relative survival nearly doubled, from about 37% in 1985–1995 to roughly 69% in 2008–2015. Gains for patients over 70 were more modest in the earlier transition period but accelerated markedly for those diagnosed from 2008 onward, when newer drug classes became standard.¹ The drugs responsible for much of this improvement include proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, all of which entered widespread use over the past two decades.

Even within relatively young patient populations, age still matters. An analysis of over 2,300 patients younger than 66 who received high-dose melphalan found that those over 60 had a statistically significant shorter overall survival compared to their younger counterparts in the same treatment group.² So the age effect is not just an old-versus-young phenomenon. It operates as a gradient, with each decade of life nudging prognosis in a measurable way.

Why Aging Changes the Disease Itself

Part of the explanation is that myeloma diagnosed in older people tends to arrive in a more advanced form. As patient age increases, the proportion presenting with the highest disease stage (ISS stage 3), poor physical performance, and certain high-risk genetic abnormalities like gain(1q) all go up significantly.³ In other words, older patients are not simply less able to tolerate treatment; their disease often looks biologically worse at the time it is discovered.

The immune system itself plays a role. The gradual decline in immune function that comes with aging, sometimes called immunosenescence, reduces the body’s ability to detect and destroy abnormal cells. This weakened surveillance is thought to contribute to why myeloma and other blood cancers are so much more common in older adults. Once myeloma takes hold in the bone marrow, it further accelerates these aging-related immune changes in the surrounding microenvironment, creating a feedback loop that benefits the cancer.⁴

When Myeloma Strikes Before 40

While myeloma is overwhelmingly a disease of people in their late 60s and beyond, a small fraction of patients are diagnosed before age 40.⁵ You might expect that younger patients, with fewer competing health problems and stronger immune systems, would do considerably better. The reality is more nuanced. A large real-world analysis from Latin America compared patients diagnosed at 40 or younger, patients aged 41 to 50, and patients 51 and older. There were no significant differences in overall survival, treatment response, or clinical features at diagnosis across all three groups.⁶

This challenges the common assumption that youth automatically confers an advantage. Some researchers suspect that myeloma in very young patients may carry distinct biological features that offset the benefit of overall better health. The topic remains an active area of study, and findings from different healthcare settings may vary. But the Latin American data are a useful reminder that age alone does not tell the whole story, at either end of the spectrum.

Fitness and Frailty Scores vs. Your Birthday

One of the most important shifts in how doctors think about myeloma prognosis is the move from chronological age to biological fitness. Geriatric assessments and frailty scoring tools are now used to sort patients into prognostic groups, guide treatment intensity, and avoid unnecessary toxicity.⁷ A fit 72-year-old and a frail 72-year-old can have wildly different trajectories, and frailty scores capture that gap in a way chronological age cannot.

A prospective study of patients aged 65 to 75 validated the International Myeloma Working Group (IMWG) frailty score in routine clinical practice. Patients classified as frail had dramatically worse progression-free survival compared to those classified as fit or intermediate, with a median of about 8 months versus roughly 30 or more months. None of the patients scored as frail had been considered eligible for stem cell transplant, and the frailty tool proved especially helpful in identifying patients in the 70-to-75 age window whose outcomes with transplant were no better than with less intensive treatments.⁸

Stem Cell Transplant in Older Patients

For decades, autologous stem cell transplant has been a cornerstone of myeloma treatment, but historically many centers imposed strict upper age cutoffs, often around 65. More recent evidence suggests this cutoff may be too rigid. One retrospective analysis comparing patients younger and older than 60 who underwent transplant found that transplant-related mortality was nearly identical in both groups (around 4%). Overall survival at five years was also comparable: about 57% in the younger group and 54% in the older group. At ten years the gap widened slightly but remained statistically insignificant. The authors concluded there was no biological justification for an age-based exclusion policy and that physiologic aging matters more than chronologic aging.⁹

A separate real-world study looking specifically at patients over 65 undergoing transplant confirmed these findings. Transplant-related mortality at 100 days was around 2% to 3% regardless of age group, and estimated five-year overall survival rates were virtually identical at about 75% and 74% in the younger and older cohorts.¹⁰ These numbers are encouraging, though it is worth noting that patients selected for transplant in these studies were already deemed fit enough for the procedure. The data argue for expanding access to transplant for fit older adults, not for transplanting everyone regardless of health status.

CAR-T Therapy and Bispecific Antibodies for Older Patients

Some of the newest weapons against myeloma, including CAR-T cell therapy and bispecific antibodies, were initially studied in populations that skewed younger. As data on older patients have accumulated, the results are broadly reassuring.

A retrospective analysis of BCMA-directed CAR-T therapy found that patients aged 70 and older had a median progression-free survival of about 13 months, compared to roughly 12.5 months in younger patients. Rates of serious side effects, including cytokine release syndrome and neurotoxicity, were similar between the two age groups. After adjusting for high-risk disease features, age 70 and over was not a significant predictor of worse overall survival.¹¹ A subgroup analysis from the KarMMa trial of idecabtagene vicleucel (ide-cel) showed overall response rates between 84% and 90% in patients aged 65 and older, with a duration of response comparable to the full study population.¹² In a cohort of patients 70 and older treated at a single center, the overall response rate reached 89%, with a one-year overall survival of 71% and a one-year relapse-free survival of 62%.¹³

Bispecific antibodies, a newer class of immunotherapy that redirects a patient’s own immune cells to attack myeloma, show a similar pattern. A study of BCMA-directed bispecific antibodies found an 80% overall response rate in patients classified as frail, compared to 73% in non-frail patients, with no statistically significant difference between the groups.¹⁴ A separate analysis of bispecific antibodies in older patients likewise found no significant differences between frail and non-frail groups in response rates, one-year progression-free survival, one-year overall survival, or rates of severe side effects.¹⁵ The collective message is that these therapies can work well for older patients, provided the side effects are managed proactively.

Complications That Shape Prognosis Differently by Age

Two of the most common myeloma-related complications, kidney damage and bone fractures, interact with age in ways that affect survival.

Kidney impairment at diagnosis is more frequent in older patients. A Mayo Clinic study of nearly 200 patients with significantly reduced kidney function at the time of diagnosis found that some improvement occurred in 82% of them, with a median time to best kidney function of about four months. Patients who received newer drug-based induction therapy had a much higher rate of complete kidney recovery compared to those who did not (40% versus 16%).¹⁶ This is hopeful, because it means kidney damage at diagnosis is not necessarily permanent, especially with effective myeloma treatment.

Fractures tell a more surprising story. A population-based study found that myeloma patients who had a fracture had a higher risk of death regardless of age. But the relative increase in death risk from fractures was actually more pronounced in patients diagnosed before age 70 than in those diagnosed at 70 or older. The hazard ratio for death in younger patients with fractures was about 2.3, versus about 1.9 in older patients.¹⁷ One possible explanation is that fractures in younger patients may signal more aggressive underlying disease, since these patients would otherwise be expected to have stronger bones.

From MGUS to Myeloma and the Effect of Age

Multiple myeloma almost always develops from a precursor condition called monoclonal gammopathy of undetermined significance, or MGUS, a relatively common finding in blood tests of older adults. Most people with MGUS never progress to myeloma, but age is one of the strongest predictors of who does. A systematic review and meta-analysis found that older age more than doubled the risk of progressing from MGUS to myeloma, with a pooled risk ratio of about 2.4. Interestingly, men had a somewhat lower risk of progression than women, and higher body mass index was also associated with increased progression risk. Race was not a statistically significant factor.¹⁸

This means that the age effect on myeloma prognosis actually begins upstream, before myeloma is formally diagnosed. Older people are both more likely to harbor MGUS and more likely to see it progress. Since myeloma caught early, or intercepted at the smoldering stage, can sometimes be managed more effectively, there is growing interest in whether screening older adults with known MGUS more aggressively could improve outcomes. That question remains open, but the biology makes the case for paying attention.

Social Deprivation and Outcome Gaps

Age and biology do not operate in a vacuum. An analysis using the ASH Research Collaborative Data Hub found that higher social deprivation, measured by the Social Deprivation Index, was significantly associated with worse overall survival in patients receiving modern myeloma induction therapy. Importantly, the study concluded that social deprivation across racial groups, rather than race and ethnicity alone, may be driving differential outcomes. Adjusting for factors like the deprivation index was critical to interpreting survival data by race.¹⁹ For older patients, who are more likely to live on fixed incomes or face transportation barriers, this social dimension of prognosis can compound the biological disadvantages of age.

Secondary Cancers After Myeloma Treatment

As patients live longer with myeloma, the risk of developing a second, unrelated cancer becomes more relevant. A nationwide case-control study found that myeloma patients had a roughly 60% higher risk of developing any secondary malignancy compared to matched controls. The increase was driven almost entirely by blood cancers: the risk of a secondary hematologic malignancy was about eight times higher, and the risk of treatment-related myeloid cancers was about twelve times higher. There was no significant increase in non-blood cancers. Patients who had undergone stem cell transplant had a slightly higher cumulative incidence of secondary cancers than those who had not.²⁰ This risk is worth knowing about, especially for younger myeloma patients who may have decades of post-treatment life ahead of them. It does not negate the benefit of treatment, but it is part of the long-term picture that patients and their doctors factor into therapy choices.

Treating Patients Over 80

Patients in their 80s represent a growing share of myeloma diagnoses as the population ages, but they are chronically underrepresented in clinical trials. Real-world data on octogenarians show the practical challenges. Even when doctors started with a low dose of lenalidomide, a widely used oral drug, nearly half of these patients still required further dose reductions due to side effects.²¹ That does not mean treatment is futile; it means that in this age group, the margin between therapeutic benefit and toxicity is narrow, and close monitoring is essential. Frailty scoring tools become especially valuable here, since the gap between a healthy and a frail 82-year-old is enormous.

Quality of Life During Treatment for Older Adults

Survival numbers are one thing, but what about how patients actually feel while being treated? A prospective study of older adults with newly diagnosed myeloma tracked both geriatric assessments and quality-of-life measures over six months of treatment. Mental health scores improved significantly, and objective physical performance, measured by a timed walking test, remained stable or improved in nearly all participants.²² This finding pushes back against the fear that treatment for myeloma in older patients inevitably means a steep decline in daily function. Effective myeloma control can improve how patients feel, partly because it alleviates symptoms like bone pain and fatigue that the disease itself causes.